Clear All
12482 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
72606-0559-02 72606-0559 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Dec 1, 2019 In Use
72606-0558-01 72606-0558 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jan 6, 2020 In Use
72606-0557-01 72606-0557 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 6, 2019 In Use
72606-0556-01 72606-0556 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 6, 2019 In Use
72606-0555-01 72606-0555 Capecitabine Capecitabine 500mg 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov 6, 2019 In Use
72606-0554-01 72606-0554 Capecitabine Capecitabine 150mg 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov 6, 2019 In Use
72606-0059-01 72606-0059 Denosumab-bmwo Denosumab-BMWO 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Sep 10, 2025 In Use
72606-0058-01 72606-0058 Denosumab-bmwo Denosumab-BMWO 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Sep 10, 2025 In Use
72606-0038-01 72606-0038 Denosumab-bmwo Osenvelt 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jul 2, 2025 In Use
72606-0037-01 72606-0037 Denosumab-bmwo Stoboclo 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jul 2, 2025 In Use
72606-0012-01 72606-0012 Bevacizumab-adcd Vegzelma 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 3, 2023 In Use
72606-0012-10 72606-0012 Bevacizumab-adcd Vegzelma 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 3, 2023 In Use
72606-0011-01 72606-0011 Bevacizumab-adcd Vegzelma 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 3, 2023 In Use
72606-0011-10 72606-0011 Bevacizumab-adcd Vegzelma 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 3, 2023 In Use
72603-0927-01 72603-0927 DASATINIB DASATINIB 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
72603-0926-01 72603-0926 DASATINIB DASATINIB 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
72603-0925-01 72603-0925 DASATINIB DASATINIB 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
72603-0924-01 72603-0924 DASATINIB DASATINIB 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
72603-0923-01 72603-0923 DASATINIB DASATINIB 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
72603-0922-01 72603-0922 DASATINIB DASATINIB 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
72603-0507-01 72603-0507 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug 1, 2025 In Use
72603-0450-01 72603-0450 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Apr 1, 2025 In Use
72603-0425-01 72603-0425 Pemetrexed disodium Pemetrexed 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Oct 1, 2024 In Use
72603-0420-01 72603-0420 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan 11, 2024 Mar 31, 2027 In Use
72603-0411-01 72603-0411 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral May 10, 2019 May 11, 2019 In Use

Found 12482 results — Export these results